04 / Research & Publications

Research & Publications

Peer-reviewed articles, conference abstracts, and posters describing the platform’s scientific foundation and clinical development.

5Peer-reviewed articles

3Conference entries

Browse the articles, abstracts, and companion posters below. Publication and PDF links open in a new tab.

Peer-reviewed publications

International Journal of Molecular Sciences · 2025

PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model

Nevala WK, Geng L, Xie H, Stueven NA, Markovic SN. 26(7):3295.

Preclinical evaluation of PD-L1-targeted nano-immune conjugates containing paclitaxel or SN-38 in a model of triple-negative breast cancer.

View publication Open PDF

Open access · CC BY 4.0 (opens in a new tab)

Clinical Cancer Research · 2024

A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

Kalogera E, Nevala WK, Finnes HD, et al. 30(12):2623-2635.

Phase I clinical study evaluating the safety, recommended phase II dose, pharmacokinetics, and preliminary clinical activity of AB160 in previously treated gynecologic cancers.

View publication Open publisher PDF

Scientific Reports · 2017

Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab

Butterfield JT, Kim H, Knauer DJ, Nevala WK, Markovic SN. 7:14476.

Laboratory study identifying the albumin-antibody binding interactions involved in coating nab-paclitaxel nanoparticles.

View publication Open PDF

Open access · CC BY 4.0 (opens in a new tab)

Scientific Reports · 2017

Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma

Nevala WK, Butterfield JT, Sutor SL, Knauer DJ, Markovic SN. 7:45682.

Preclinical characterization of rituximab-coated nab-paclitaxel nanoparticles (AR160), including antibody binding, drug delivery, and a mouse model of B-cell lymphoma.

View publication Open PDF

Open access · CC BY 4.0 (opens in a new tab)

Cancer Research · 2016

Antibody-Targeted Chemotherapy for the Treatment of Melanoma

Nevala WK, Buhrow SA, Knauer DJ, Reid JM, Atanasova EA, Markovic SN. 76(13):3954-3964.

Preclinical study of bevacizumab-coated nab-paclitaxel nanoparticles (AB160) in a human melanoma xenograft model.

View publication Open publisher PDF

Abstracts & Posters

ASH · 2023 · LS1681 / AR160 - Abstract 4471

A First in Human Phase I Trial (LS1681) of Abraxane/Rituximab 160 nm nanoparticle (AR160) in Relapsed Refractory B-Cell Lymphomas Including Transformed Follicular Lymphoma: A Final Report

Habermann TM, LaPlant B, Micallef I, et al.

Final-report abstract and companion poster from the phase I AR160 study in relapsed/refractory B-cell lymphomas.

Open abstract (PDF) Open poster (PDF)

SGO Annual Meeting · 2023 · MC1371 / AB160

A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Metastatic Gynecological Malignancies: MC1371 (NCT02020707)

Kalogera E, Suman VJ, Nevala WK, et al.

Conference abstract and companion poster describing the AB160 gynecologic-cancer study subsequently reported in Clinical Cancer Research.

Open abstract (PDF) Open poster (PDF)

ASCO · 2020 · LS1681 / AR160

LS1681: A Phase I Trial of AR160 (Abraxane/Rituximab 160nm nanoparticle) in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL) including Transformed Follicular Lymphoma

Habermann TM, LaPlant B, Nevala WK, et al.

Trial-in-progress abstract outlining the AR160 study design and eligibility criteria; distinct from the later 2023 final report.

Open abstract (PDF)